Pharmacokinetics of vancomycin in adult cystic fibrosis patients

Although the dispositions of many antibiotics are altered in cystic fibrosis patients, that of vancomycin has not been studied. To assess vancomycin pharmacokinetics, 10 adult cystic fibrosis patients were given a parenteral dose of vancomycin (15 mg/kg) during the first 72 h of hospitalization for acute bronchopulmonary exacerbation, Blood samples were obtained at 0, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 15, and 24 h, The mean (standard deviation) weight, measured creatinine clearance, and Taussig clinical score were 51 (13) kg, 130 (39) ml/min/1.73 m(2), and 64 (13), respectively, Multicompartmental pharmacokinetic parameters were best described by a two-compartment model, The mean (standard deviation) volume of distribution, total body clearance, and terminal elimination rate constant were 0,58 (0.15) liter/kg, 91 (19) ml/min/1.73 m(2), and 0.123 (0.05) h(-1), respectively, These values were consistent with vancomycin pharmacokinetic parameters obtained in previous studies of healthy adult volunteers. Vancomycin dosages predicted by using a two-compartment Bayesian model were approximately 15 mg/kg every 8 to 12 h, There were poor correlations between clinical score or creatinine clearance and any pharmacokinetic parameter (r values of < 0.32), The coefficient of correlation between urine flow rate and total body clearance was 0.7 (P < 0.05), Adult cystic fibrosis patients exhibit a disposition of vancomycin similar to that exhibited by healthy adults, and thus cystic fibrosis does not alter vancomycin pharmacokinetics.